

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	X	NA	NA	NA

\*FHK- Florida Healthy Kids

## Buprenorphine/Naloxone Agents – NY and SC MCD ONLY

Override(s)	Approval Duration
Quantity Limit Step Therapy	1 year

Medications	Status	Strength	Quantity Limit
Buprenorphine with naloxone Sublingual Tablet	Preferred	2mg – 0.5mg	12 sublingual tablets per day*
		8mg – 2mg	3 sublingual tablets per day*
Suboxone (buprenorphine with naloxone) Sublingual Film	Preferred	2mg – 0.5mg	12 films per day*
		4mg – 1mg	6 films per day*
		8mg – 2mg	3 films per day*
		12mg – 3 mg	2 films per day*
Zubsolv (buprenorphine with naloxone) Sublingual Tablet	Non-Preferred	0.7mg-0.18mg	23 sublingual tablets per day
		1.4mg – 0.36mg	12 sublingual tablets per day
		2.9mg – 0.71mg	4 sublingual tablets per day

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	X	NA	NA	NA

\*FHK- Florida Healthy Kids

		5.7mg – 1.4mg	3 sublingual tablets per day
		8.6mg – 2.1 mg	2 sublingual tablets per day*
		11.4mg – 2.9mg	1 sublingual tablet per day
			*Indicates FDA maximum recommended dose for specific drug and dosage strength – 17.2 mg/4.2 mg
Bunavail (buprenorphine with naloxone) Buccal Films	Non-Preferred	2.1mg – 0.3mg	6 buccal films per day
		4.2mg – 0.7mg	3 buccal films per day*
		6.3mg – 1mg	2 buccal films per day
			*Indicates FDA maximum recommended dose for specific drug and dosage strength – 12.6 mg/2.1 mg

## APPROVAL CRITERIA

Requests for all non-preferred buprenorphine with naloxone products (Bunavail, and Zubsolv) for NY and SC markets may be approved for individuals who meet the following criteria:

- I. Individual meets one of the following:
  - A. Individual has been on the requested product in the previous 180 days **OR**
  - B. Individual has had a trial of one preferred buprenorphine with naloxone agent (current preferred agents: buprenorphine/naloxone sublingual tablets, Suboxone film) in the previous 180 days.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	X	NA	NA	NA

\*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.

DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol TIP 40. U.S. Department of Health and Human Services. [http://buprenorphine.samhsa.gov/Bup\\_Guidelines.pdf](http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf). Pub date 2004. Accessed July 6, 2018.

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: A Treatment Improvement Protocol. TIP 43. U.S. Department of Health and Human Services. <http://www.ncbi.nlm.nih.gov/books/NBK64164/pdf/TOC.pdf>. Pub date 2005, Rev 2012. Accessed July 6, 2018.

Substance Abuse and Mental Health Services Administration. *Federal Guidelines for Opioid Treatment Programs*. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. <http://store.samhsa.gov/shin/content//PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf>. Pub date 2015. Accessed July 6, 2018.